BD Biosciences releases flow cytometry system for in vitro diagnostics
27 Sep 2006
San Jose, Calif., USA. BD Biosciences, a segment of BD (Becton, Dickinson
and Company) (NYSE:BDX) , today announced the U.S clearance and release of
the BD FACSCanto II flow cytometry system for in vitro diagnostic (IVD) use.
This new benchtop analyzer supports the first six-colour flow cytometry
IVD application for routine HIV/AIDS monitoring using a highly efficient
one-tube test. Health professionals regularly use flow cytometry to obtain
CD4 test results to make important treatment decisions in HIV-infected
patients, most notably when the disease has progressed to the point where
initiation of antiretroviral treatment (ARV) would be beneficial.
The BD FACSCanto II system offers a range of turnkey IVD applications, as
well as the flexibility and cutting-edge performance required for complex
life science and clinical research applications. The BD FACSCanto II system
demonstrates BD Biosciences' continued commitment to the growing need for
IVD products. The system is also CE-IVD marked and was released in Europe
earlier this year.
The BD FACSCanto II system assists laboratories in achieving quality data
quickly and efficiently, offering users high-fluorescence sensitivity,
industry-leading low sample contamination of less than 0.1% between tests,
and processing speeds of up to 10,000 events per second. Due to its unique
performance characteristics, the BD FACSCanto II system greatly facilitates
rare event analysis, an important feature for laboratories of all types.
Whether used for clinical research or IVD testing, the BD FACSCanto II
system is designed with many automation features that increase laboratory
efficiency and productivity. Its integrated fluidics cart holds all fluids
necessary for routine operation and maintenance, facilitating automated
system cleaning, startup, and shutdown routines to help laboratories focus
on what's important — analysis and reporting of data.
"For more than 30 years, BD flow cytometers have paved the way for state-
of-the-art cell analysis, becoming the method of choice for researchers and
clinicians who measure and chart characteristics and properties of cells,
particularly cells of the immune system," said Bill Rhodes, President, Cell
Analysis. "The design of the BD FACSCanto II system brings all of our
expertise to bear, providing the latest tool to advance potentially
lifesaving research and meet the complex needs of the 21st century clinical